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South Africa and the COVID-19
vaccine
debate
Scientists, public health experts and politicians have been telling 
us that, to stop Covid-19,   we need to embark on a massive vaccine 
rollout. But do we really need to vaccinate more than 70% of  our 
population to stop this virus? What is the science telling us? 
What do we know about the Covid-causing virus?
To make sense of  the need for a vaccine, we need to look at this “new” 
or novel coronavirus first. The Severe Acute Respiratory Syndrome 
Coronavirus-2 (SARS-CoV-2), the virus behind Covid-19, is only 
the seventh human coronavirus identified. This virus is not nearly as 
deadly as two of  its “cousins”, SARS-CoV and MERS-CoV, which 
had a 10% and 35% death rate, respectively. According to global 
statistics, only about 15-18% of  all Covid-19 cases develop into 
severe or critical cases that require treatment with oxygen, with about 
5% of  all Covid-19 cases requiring intensive care. And thankfully 
“only” about 2.0-3.5% of  Covid-19 cases die. We now know with 
some certainty that advanced age (older than 60); being male; and 
the presence of  other pre-existing medical conditions such as obesity, 
diabetes, heart disease, certain chronic lung diseases and kidney 
disease are among the major factors linked to severe Covid-19 and an 
increased risk of  death. This does not suggest that young children, the 
youth and women are immune to the disease. They can and do catch 
the virus – even if  they don’t always exhibit the associated symptoms 
– and can and do pass it on to others. Importantly, only those who 
develop severe Covid-19 are at risk of  dying. 
Why are people dying of  Covid-19?
It is not SARS-CoV-2 that kills directly, but rather it is the body’s 
own response to the virus that causes damage to the body. In all viral 
infections, the infected person’s built-in immune system, once alerted 
to the presence of  the invading virus – identified by the body as a 
foreign substance – is activated and, in healthy individuals, launches 
an attack against said antigen. The main purpose of  the immune 
response is to stop the spread and movement of  the virus throughout 
the body. If  the pathogen manages to evade the first-line physical 
barriers and enters the body, the chemical and cellular immune 
response is activated. It is then that the body releases cells (notably B 
cells and T cells) that attack the pathogen, or produces special proteins 
known as antibodies. Think of  these antibodies as the sentinels of  the 
immune system; they attach themselves to the virus, and attract cells 
that then destroy said antigen. 
Typically this immune response is carefully regulated by the body, to 
ensure that it destroys only the virus, and not the host itself  – that is, 
humans. With Covid-19, however, the immune system “overreacts”. 
This leads to the blood-clotting system malfunctioning, as well as to 
the overproduction and release of  inflammatory proteins known as 
cytokines. This results in the formation of  blood clots and what’s 
known as hyperinflammation, respectively. Hyperinflammation 
throughout the body, in particular the organs, can lead to multiple 
organ damage and failure. On the other hand, blood clots forming 
in blood vessels can obstruct blood flow, and could result in deep-vein 
thromboses in the legs, clots in the lungs, and stroke-causing clots in 
the brain.
Because the body’s immune system, inflammation and clotting are 
linked, anything that causes the regulation of  these systems to get out 
of  whack, and the balance between the three to be off, can lead to 
severe or critical Covid-19, and in some cases, death. 
Can we save lives in the absence of  effective Covid-19 
vaccines?
To effectively treat Covid-19, we need to be able to identify individuals 
at risk of  developing severe or critical Covid-19 early in the clinical 
development of  the disease. Then, equally importantly, we need drugs 
that are effective in treating the disease. How far have we advanced to 
address these two issues?
As mentioned, we know which part of  the population is at greater risk 
of  developing severe Covid-19; and keep in mind that not everyone in 
these risk groups will develop severe Covid-19 – just about 15% do in 
the end. Then, when someone becomes infected, we can just analyse 
the combination of  various early symptoms, predict who is at greater 
risk of  developing critical Covid-19, and have some idea of  who is at 
increased risk of  dying. Used together with the presence of  certain 
bio-markers in patients – biological molecules found in body fluids 
or tissues that are a measure of  body processes and/or indication of  
disease – we can predict, with a high degree of  accuracy, not only 
the risk of  illness (morbidity), but also the risk of  death (mortality) of  
individual patients eight to ten days in advance. This should provide 
clinicians with enough time to start pharmaceutical interventions.
I will not look at all the possible drugs used in the treatment of  
severe Covid-19. Instead, let’s look at two relatively cheap drug 
options that have received widespread support, and that are readily 
available in South Africa. Dexamethasone, a steroid widely used to 
treat inflammation, was the first drug shown to save lives in people ill 
with Covid-19, in what University of  Oxford scientists called a “major 
breakthrough”. Trials show dexamethasone reduces death rates by a 
third among seriously ill patients. The South African Department 
of  Health (SADoH) issued an advisory to “recommend the use of  
dexamethasone (or an equivalent steroid) for all Covid-19 patients on 
ventilators or requiring non-invasive supplementary oxygen”.
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Researchers report that hospitalised Covid-19 patients treated with 
blood thinners (usually low molecular weight heparin) have improved 
clinical outcomes and this is associated with lower death rates. In 
fact, the SADoH guidelines recommend “the use of  blood thinners 
for all hospitalised patients with Covid-19. The blood thinner can 
be given in two different doses: low-dose to reduce the risk of  blood 
clots developing and high-dose to treat blood clots that have already 
developed.” 
It is important to note that these drugs are used to treat severe or 
critical Covid-19 in patients requiring hospitalisation and ventilation 
only, and are not recommended for routine use in mild to moderate 
Covid-19 cases.
What is “herd immunity”? 
The World Health Organisation (WHO) defines herd immunity, or 
“population immunity”, as “the indirect protection from an infectious 
disease that happens when a population is immune either through 
vaccination or immunity developed through previous infection”. 
In other words, it’s really about preventing the spread of  a disease. 
Depending on how contagious a disease is, between 60% and 90% 
of  a given population must have some form of  immunity to stop the 
disease-causing organism from spreading. In South Africa, scientists 
estimate that we need 60% to 70% of  our population to be immune 
to Covid-19 to stop the spread. How does immunity from natural 
infection compare to immunity from vaccination? To achieve herd 
immunity against Covid-19 in South Africa and minimise deaths, 
should we be looking at vaccination only, or should we be looking at a 
vaccine-natural infection combination approach? 
Some scientists speculate that compared to natural infection, Covid-19 
vaccines offer “better” protection, with possibly longer periods of  
protection. Yet, with the vaccine having been developed and rolled 
out over only the past few months, how much do we know about 
immunity from Covid-19 vaccines?
Figure 1: The principles of  herd immunity and safety measures explained (Created with BioRender.
com. Based on “Principles of  Herd Immunity and Social Distancing”, by BioRender.com (2021). 
Retrieved from https://app.biorender.com/biorender-templates)
Unfortunately, the answer to this question is that we know very little. 
We do not know if  immunity from either will last months or, hopefully, 
years. For now, only time and further research will tell. Obviously 
researchers are hoping for long-term immunity, and there is a growing 
consensus that we will likely see immunity lasting one to three years. In 
reality, though, the duration “could be longer or shorter” and will only 
be determined by studying  people who have received the vaccine.
And don’t forget that we have immune data from the other six human 
coronaviruses. For the four “common cold” coronaviruses, immunity 
typically lasts between one and three years; this means that people can 
be infected multiple times over the course of  their lives. For the two 
more deadly coronaviruses, SARS-CoV and MERS-CoV, antibodies 
last for one to three years, but the T and B cells – the determinants 
of  long-term immunity – appear to last from five years to decades. 
Very importantly, too, whereas the current Covid-19 vaccines use one 
viral protein to stimulate an immune response, natural infections also 
stimulate antibody production against various other viral proteins; 
these other antibodies have also previously been shown to play a 
central role in immunity. 
Will we see the same for SARS-CoV-2 as we see for the other human 
coronaviruses? Does this mean that natural immunity will offer better 
protection against SARS-CoV-2 variants? Does this mean that it will 
offer better long-term protection? We simply do not know yet, and 
only time will tell.
8
Figure 2: Neutralising antibodies prevent the virus from entering the cell (Created with BioRender.com. Based on 
“Recruitment of  T and B Cells by Antigen-presenting Cells (APCs)” by BioRender.com (2021). Retrieved from 
https://app.biorender.com/biorender-templates)
What is meant by vaccine “effectiveness” and “efficacy”?
When a vaccine is developed, we ask the questions “Does the vaccine 
work?” (efficacy) and “Does the vaccine help people?” (efficiency). 
Efficacy, which is tested under very specific conditions, in which people 
are randomly assigned to “treatment” vs “no-treatment” groups, does 
not necessarily equal effectiveness, and could overestimate the impact 
of  a vaccine’s impact in “real-world conditions”. Once the efficacy 
of  a vaccine has been established, its effectiveness is determined in 
observational studies, where factors such as other medications people 
are taking, underlying chronic co-morbidities, viral mutants, the age 
of  those vaccinated, and how the vaccine is stored and administered 
under everyday conditions, can reduce how effective the vaccine 
is at preventing disease. In South Africa, we are now seeing in real 
time how the difference between “efficacy” and “effectiveness” for 
the University of  Oxford/AstraZeneca vaccine is playing out. The 
vaccine, which had a reported efficacy of  95% against the wild-type 
(original) SARS-CoV-2, now has a reported 25% effectiveness in 
younger people infected with a SARS-CoV2 mutant. A virus cannot 
replicate – make more of  itself  – without a host; in this case, the host 
is us. Each time the virus enters a human cell, it first has to make 
more of  its own genetic material, which will ultimately be used to 
make more copies of  the virus. This type of  virus does not have the 
ability to correct mistakes when it copies its own genetic material, 
and these resultant changes are known as mutations. This a natural 
process and the majority of  the mutations will not result in changes to 
how the virus behaves in the host. Every so often, though, a mutation 
arises that could provide the virus with a selective advantage in the 
host, such as allowing the virus to enter human cells more easily, or 
to evade the body’s immune cells. Viruses with these small genetic 
changes (or mutations) are known as “variants”. This is what we have 
observed first-hand in some parts of  the world where variants have 
been identified. Data now show that some of  these variants can enter 
human cells “better” and spread “easier” between people. Worryingly, 
some research groups have reported that antibodies from vaccines and 
natural infections are not as effective against some variants as they 
are against the original virus, rendering some vaccines less effective 
in certain demographics of  our population. Thankfully, as far as we 
know, none of  the current variants cause more severe Covid-19.
What are the Covid-19 vaccines considered for South 
Africa? 
Vaccines are meant to mimic natural infections and aim to trick 
the body into activating its immune system. So, similar to natural 
infections, the antibodies and immune cells generated after vaccination 
will protect the body when exposed to the actual virus. The first batch 
of  Covid-19 vaccines currently considered in South Africa all rely on 
their acting upon the SARS-CoV-2 Spike protein (S). The S is the 
viral protein that sticks out of  the virus’s surface, giving it its “crown-
like” appearance when viewed under a very specialised electron 
microscope. This is also the virus protein that binds to the human cell 
protein (ACE2), allowing the virus to enter the cell. These vaccines 
employ different technological approaches to prime the body’s 
immune system to recognise and fight SARS-CoV-2. But, in the end, 
all of  them are aimed at stimulating the production of  neutralising 
antibodies in the body; these antibodies are aimed at preventing the 
virus from entering the cell by binding to the virus S and preventing 
attachment of  the virus to the human cell receptor, ACE2.
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Figure 3: Vaccines considered for use in South Africa (Created with BioRender.com. Based on “Covid-19 Vaccine Candidate: BNT162 (a1, b1, 
b2, c2) (BioNTech)”, “Covid-19 Vaccine Candidate: AZD1222 (University of  Oxford & AstraZeneca” and “Covid-19 Vaccine Candidate: 
CoronaVac (Sinovac Biotech)” by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates)
The Pfizer/BioNTech and Moderna vaccines use the same type of  
technology. These are mRNA vaccines that code for the coronavirus’s 
S and are encapsulated in a lipid nanoparticle. After it is injected, the 
recipient’s cells then make S, and the body also produces antibodies 
to S. Whereas the Pfizer/BioNTech vaccine has to be stored at -70°C, 
Moderna’s vaccine can be kept in a standard refrigerator for up to 30 
days, and can be stored for up to six months at -20°C. 
The AstraZeneca, Johnson & Johnson and Sputnik V vaccines depend 
on technology based on an inactivated common cold virus. They 
contains the genetic material of  S. The AstraZeneca vaccine can 
be stored and transported in normal refrigerated conditions – about 
2º to 8°C – for at least six months. Whereas the other four vaccines 
mentioned above require two doses, about four weeks apart, the J&J 
vaccine requires a single dose. 
SinoVac is different from the other Covid-19 vaccines considered for 
use in South Africa in that it an inactivated SARS-CoV-2 vaccine. 
Unfortunately, based on current data, these vaccines do not effectively 
protect us from SARS-CoV-2 infection and, in about 30% of  cases, 
do not prevent those infected from spreading the virus. They are 
effective in preventing Covid-19, though, especially the severe and 
critical forms of  the disease. And because the vaccines do not protect 
from infection or spread, the potential for the emergence of  virus 
variants is still a possibility.
As for the long-term safety of  the vaccines, we simply to not have 
the data. In fact, the vaccines have not been tested on children and 
pregnant or lactating women, so we do not know what the potential 
long-term effects could be on the baby in the latter cohort. The 
vaccines have just not been around long enough. 
So should you take the vaccine?
In the end, for people to make an informed consent decision about 
taking the vaccine or not – as for any other medical procedure – 
they need access to all available data. In my opinion, in the end, to 
vaccinate or not should be based on a risk-based approach. Everyone 
should weigh their risk of  developing severe or critical Covid-19 with 
the potential risks, even though potentially small, associated with the 
vaccines; whichever outweighs the other, should inform your decision 
to vaccinate or not. 
Finally, there is a growing consensus that herd immunity will not be 
achieved for Covid-19. It is my opinion that we should minimise the 
spread of  the virus for as long as possible by maintaining the personal 
prevention measures of  wearing a mask, sanitising our hands, physical 
distancing and self-isolating when feeling ill. But, equally important, 
we should protect those at high risk of  developing severe and critical 
Covid-19 by vaccinating them. Once we have an adequate vaccine 
protection in this cohort – the elderly, with co-morbidities, as well as 
frontline medical workers – we could ease the use of  the personal 
prevention measures with confidence.
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Who should be vaccinated? 
In general, vaccines are more effective in younger people than the 
elderly and young children, because the immune system in young 
adults is more robust; this often results in vaccines being less effective 
in the latter two. Some public health experts and politicians claim 
that because of  the nature of  the Covid-19 pandemic “no one may 
be safe until everyone is safe”, and that as long as we allow the virus 
to infect many people, we will “allow mutations and increase the risk 
of  death”. Hence they argue that herd immunity may not be achieved 
if  we do not vaccinate everyone, including children and pregnant or 
lactating women. 
Traditionally, we would only consider vaccinating children if: (1) the 
disease has the potential to cause severe and widespread illness or 
deaths in children; (2) there is a residual pool of  young hosts spreading 
a deadly disease to others; (3) a subgroup of  children, with pre-existing 
medical conditions, are vulnerable to the disease-causing organism; 
and (4) the disease has resulted in the suspension of  educational, social 
and athletic activities crucial to normal development. In children, 
Covid-19 symptoms are mostly mild, and a very low death rate has 
been reported. Moreover, deaths are almost exclusively linked to 
serious co-morbidities and in infants under one year of  age. 
There is global evidence that the closure of  educational, social and 
athletic activities have not significantly prevented the spread of  
Covid-19 among children. In fact, we now see that other community- 
and household-based factors are chiefly responsible for the spread 
of  the disease in children. Even though children can be infected and 
spread the virus to others, they are not the main source of  spread. So, 
based on previous vaccination criteria, as well as current evidence, 
the large-scale Covid-19 vaccination of  children appears not to be 
warranted. 
